The $4.25 million drug-price headline refers to Lenmeldy (atidarsagene autotemcel), a one-time gene therapy for children with certain early-onset forms of metachromatic leukodystrophy (MLD). Orchard Therapeutics announced that U.S. wholesale acquisition cost (WAC) on March 20, 2024. WAC is a list price before rebates and negotiated discounts—not necessarily what a health plan or public program ultimately pays.
What is the $4.25 million drug?
Lenmeldy is a gene therapy for children with specified forms of MLD, an inherited disease associated with mutations in the gene that encodes arylsulfatase A (ARSA). Orchard Therapeutics describes MLD as rapidly progressive, irreversible and ultimately fatal. The company reported an incidence of approximately one in 100,000 live births, citing its announcement and the literature it references; that is a manufacturer-reported estimate, not an independently verified current rate.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
The Life-Changing Power of Gene Therapy: DNA-Editing Technology that Revolutionizes Modern Medicine | $8.99 | Buy on Amazon |
| 2 |
|
Handbook of Cell and Gene Therapy | $50.39 | Buy on Amazon |
| 3 |
|
Gene Therapy | $113.48 | Buy on Amazon |
| 4 |
|
A Handbook of Gene and Cell Therapy | $83.19 | Buy on Amazon |
| 5 |
|
Textbook of Gene Therapy: Principles and Applications | $99.99 | Buy on Amazon |
Lenmeldy is indicated for children with pre-symptomatic late-infantile MLD, pre-symptomatic early-juvenile MLD, or early-symptomatic early-juvenile MLD. It is not Zolgensma: that is a separate therapy for spinal muscular atrophy. Florida’s Agency for Health Care Administration (AHCA) listed Lenmeldy at $4.25 million WAC and Zolgensma at $2.5 million WAC in its January 2026 review of cell and gene therapies; both figures are list prices before rebates and discounts.
Why the list price is not necessarily the amount paid
Orchard announced a U.S. WAC of $4.25 million for one-time treatment in March 2024. Florida AHCA explains in its January 2026 report that WAC precedes federal and supplemental Medicaid rebates and negotiated discounts, so actual Medicaid net costs may be lower. The announced figure should not be read as a universal invoice or as the amount every insurer pays.
#1 Best Overall
Orchard said the Institute for Clinical and Economic Review (ICER) set a health-benefit price benchmark of up to $3.94 million at a threshold of $150,000 per equal-value life-year, using a modified societal perspective. That benchmark is reported here through Orchard’s March 2024 announcement; it is an assessment benchmark, not a statement of a particular payer’s negotiated price.
Orchard also said it offered outcomes- and value-based agreements to private and government payers. Such arrangements do not establish that every eligible child is covered, or reveal an individual family’s out-of-pocket cost. Coverage, net price and current treatment-center availability depend on current payer and provider arrangements that are not established by the cited launch and state-report information.
Rank #2
How the treatment works
Lenmeldy uses a child’s own hematopoietic stem cells. The cells are collected, modified outside the body with functional copies of ARSA using a lentiviral vector, then infused after high-dose chemotherapy. Because it involves cell collection, laboratory modification, chemotherapy and reinfusion, it is a specialist-administered hospital treatment—not a consumer purchase. Florida AHCA describes it as requiring highly specialized treatment centers.
What the clinical evidence showed
Orchard said FDA approval was supported by data from 37 pediatric patients enrolled in two single-arm, open-label studies or treated through European expanded-access frameworks. The outcomes were compared with natural-history data, not with a randomized control group.
Rank #3
Pre-symptomatic late-infantile MLD
Orchard reported that all treated children in this subgroup were alive at age six, compared with 58% in the natural-history group. At age five, 71% could walk without assistance, and 85% had normal language and performance IQ scores. These are manufacturer-reported outcomes from a small, non-randomized evidence base; the subgroup, ages and natural-history comparison matter when interpreting the figures.
Early-juvenile MLD
For children with pre-symptomatic or early-symptomatic early-juvenile MLD, Orchard reported slowing of motor and/or cognitive disease. The announcement does not give a single outcome figure in the cited summary that can be directly compared with the late-infantile results.
Rank #4
Risks and follow-up
Orchard lists fever, low white blood cell counts, mouth sores, respiratory and other infections, rash, and enlarged liver among common side effects. Its announcement also describes possible blood clots, encephalitis and a potential risk of blood cancer. The company said no blood cancer cases had been seen among treated patients at the time of that announcement.
Monitoring is part of the treatment’s long-term burden. Orchard recommends lifelong monitoring for hematologic malignancies, including annual complete blood counts and integration-site analysis as warranted for at least 15 years; it also advises monitoring neutrophil counts and delayed platelet engraftment.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What families should verify about access
In its March 2024 launch announcement, Orchard said five U.S. specialist treatment centers were being activated or qualified and that Orchard Assist would provide individualized support to eligible families who enrolled. Those are launch-era statements, not confirmation of current center availability or present payer coverage. Families and clinicians should verify current eligibility, coverage terms, treatment-center status and expected out-of-pocket costs directly with the insurer or public program and a qualified treatment center.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
